• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Response of lymphocytes and cytokines in patients with superficial bladder cancer treated with 1 mg of BCG vaccine instillations].

作者信息

Rivera P, Inostroza J, Orio M

出版信息

Actas Urol Esp. 1996 Oct;20(9):812-7.

PMID:9065092
Abstract

It was carried out a study of lymphocytes CD3, CD8 and cytokines in the blood of 13 patients, with superficial bladder cancer, and treated by instillations with BCG vaccine, with a dose of 1 mg. in an annual scheme, being related them before and after treatment. A control group of 10 patients without bladder cancer and without vaccine instillations were compared. The measurings took place in a blind way, previous to BCG treatment, 15 days, 3 days, 3 months, 6 months and 12 months of treatment. It was observed in postBCG treatment, a significative increase in the count of CD3 lymphocytes and the CD4/CD8 cociente (both, P < 0.05). Concerned to cytokines, a significative increase was only demonstrated by interleukin-2 in the post BCG group (P < 0.05). In both (lymphocytes and cytokines) the control groups didn't demonstrate statistics signification. The studies where analysed by means of ANDEVA test, under 2 x 2 cross over design, student t and no parametric tests. In conclusion, bladder instillations of 1 mg. of BCG vaccine as prophylactic treatment of superficial bladder cancer, it's capable of developing lymphocytic answer and stimulate the increase of interleukin-2 in the serum.

摘要

相似文献

1
[Response of lymphocytes and cytokines in patients with superficial bladder cancer treated with 1 mg of BCG vaccine instillations].
Actas Urol Esp. 1996 Oct;20(9):812-7.
2
Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin.卡介苗膀胱内免疫治疗后浅表性膀胱癌患者尿液中的白细胞和细胞因子
In Vivo. 1991 Nov-Dec;5(6):671-7.
3
Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.卡介苗膀胱内免疫治疗后膀胱肿瘤患者黏膜免疫细胞的变化。
Oncol Rep. 2001 Mar-Apr;8(2):257-61.
4
Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.卡介苗膀胱内灌注在接受类固醇治疗和免疫功能低下患者中的安全性和有效性。
J Urol. 2006 Aug;176(2):482-5. doi: 10.1016/j.juro.2006.03.066.
5
The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients.卡介苗预防性治疗患者中CD2 +外周血淋巴细胞亚群与膀胱癌复发之间的关联。
Br J Cancer. 1999 Mar;79(7-8):1162-7. doi: 10.1038/sj.bjc.6690185.
6
[The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].卡介苗诱导的外周免疫反应的发展提示了浅表性膀胱癌需要延长卡介苗治疗时间。
Acta Urol Belg. 1997 Mar;65(1):1-4.
7
Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.浅表性膀胱癌卡介苗膀胱内灌注治疗期间针对结核菌素和抗原85复合物的细胞和体液反应的演变
Acta Urol Belg. 1994 Sep;62(3):63-8.
8
Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.卡介苗膀胱灌注对浅表性膀胱癌的持续预防作用:一项随机前瞻性研究中的平滑风险分析
Urology. 2006 Mar;67(3):545-9. doi: 10.1016/j.urology.2005.09.045.
9
T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer.卡介苗治疗浅表性膀胱癌1个疗程和2个疗程后有反应和无反应患者的辅助性T细胞1/2淋巴细胞尿细胞因子谱
J Urol. 2001 Dec;166(6):2142-7.
10
[Urinary leukocytes as a new prognostic marker of therapeutic response and of adverse effects associated with the maintenance treatment with endovesical BCG, for the prophylaxis of superficial bladder tumors].
Prog Urol. 2001 Dec;11(6):1242-50.